Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
5
×
boston blog main
clinical trials
fda
5
×
life sciences
national blog main
boston top stories
deals
alexion pharmaceuticals
investing
national top stories
rare disease drugs
roche
san francisco blog main
akouos
alnylam pharmaceuticals
amyotrophic lateral sclerosis (als)
astellas pharmaceuticals
autoimmune disorders
avapritinib
biotech ipos
blueprint medicines
boehringer ingelheim
california institute for biomedical research
complement system
cstone pharmaceuticals
decibel therapeutics
dicerna pharamceuticals
dyne therapeutics
eli lilly
european medicines agency
fisogatinib
flatiron health
frequency therapeutics
genentech
generalized myasthenia gravis
harvard university
hearing loss
hepatitis b
What
drug
5
×
medicines
candidate
developing
disease
fda
ipo
muscle
pharma
pharmaceuticals
roche
team
therapeutics
affects
alternative
americans
approval
approved
autoimmune
blueprint
brings
cancer
caught
causing
company
currently
date
deal
dicerna
disorders
dyne
dyne’s
expensive
eye
frequency
gene
genetic
hearing
hepatitis
intended
Language
unset
5
×
Current search:
fda
×
drug
×
unset
×
boston
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds